As clinical trials are the gold standard for evidence-based medicine, it is essential for researchers to be as inclusive as possible with respect to study populations when designing trials. A recent cross-sectional study of plaque-type psoriasis trials found that such studies were plagued by intrinsic “ethnoracial disparities.” The analysis found that vast majority of participants (85.8%) in studies reporting ethnoracial data were classified as White–Black/African-Americans only accounted for 3%. In order to provide clinically useful answers for diverse populations trials must reflect the real-world populations being treated. Read more here.
(Source: Gerome Lipper, MD; Medscape, 10/2/20)